Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ is proud to announce its nomination for the prestigious 2023 Prix Galien USA Awards in the category of “Best Digital Health Solution.” The Prix Galien Awards, organized by The Galien Foundation, recognize and celebrate groundbreaking innovations in the life sciences industry that significantly advance human health and well-being.
“We are honored to see Science 37 recognized as a nominee for the Prix Galien USA Awards,” said David Coman, CEO of Science 37. “This nomination is a testament to our team’s dedication to accelerating clinical research by enabling universal trial access for patients through our Metasite. We are proud to be part of an exceptional group of innovators striving to make a positive impact on patients’ lives.”
Science 37 has redefined the clinical trial landscape, as a virtual site that transforms research by enabling patients to participate in trials from the comfort of their homes. With investigator oversight, the Metasite removes boundaries and enhances experience with flexible telemedicine visits, remote data capture, and convenient scheduling times. Powered by a proprietary platform that enables eConsent, ePRO, telemedicine, scheduling, and wearable/ device integration, the Metasite drives unified study orchestration, greater compliance, and high-quality data—reaching patients, wherever they are.
The 2023 Prix Galien USA Forum, taking place on October 26, 2023, at the Alexandria Center for Life Science in New York City, will feature the nominees for “Best Digital Health Solution” among others, and later that evening, during the Prix Galien USA Awards Ceremony at the American Museum of Natural History in New York City, the winners in all categories will be unveiled and honored.
“We extend our congratulations to Science 37 for their remarkable contributions to clinical research,” said Galien Foundation Chair, Bruno Cohen. “The Awards represent endless determination in the pursuit of life-changing innovation, and we are excited to announce the 2023 nominations.”
About Science 37
Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical research by enabling universal trial access for patients. Through our Metasite™ we reach an expanded population beyond the traditional site, delivering on our goal of clinical research that works for everyone—with greater patient diversity. Patients gain the flexibility to participate from the comfort of their own homes, at their local community provider, or at a traditional site when needed. Our Metasite is powered by a proprietary technology platform with in-house medical and operational experts that drive uniform study orchestration, enabling greater compliance and high-quality data. To learn more, visit www.science37.com, or email science37@science37.com.
About the Galien Foundation
The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.
The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa. The Prix Galien was created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the products offered by Science 37 and the markets in which it operates, and Science 37’s anticipated growth and profitability. These forward-looking statements generally are identified by the words “believe,” “can,” “could”, “seek”, “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “might”, “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the ability to maintain the listing of Science 37’s securities on The Nasdaq Stock Market LLC, (ii) volatility in the price of Science 37’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Science 37 operates, variations in performance across competitors, changes in laws and regulations affecting Science 37’s business, changes in its capital structure, and general economic and financial market conditions, including fluctuations in currency exchange rates, economic instability, and inflationary conditions (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional opportunities, (iv) the risk that Science 37 may never achieve or sustain profitability, (v) the risk that Science 37 will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all, (vi) failure to realize anticipated cost savings, and (vii) risks related to general economic and financial market conditions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Science 37’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 6, 2023 and in the other documents filed by Science 37 from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Science 37 assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Science 37 does not give any assurance that Science 37 will achieve its expectations.
MEDIA INQUIRIES:
Grazia Mohren
Science 37
PR@science37.com
INVESTOR RELATIONS:
Steve Halper
LifeSci Advisors
Investors@science37.com
